What Are the Chances of NeuBase Therapeutics Inc (NBSE) Stock Making a Comeback?

H.C. Wainwright raised the price target for the NeuBase Therapeutics Inc (NASDAQ:NBSE) stock to “a Buy”. The rating was released on February 12, 2021, according to finviz. In their research brief published November 21, 2019, Oppenheimer analysts initiated the NeuBase Therapeutics Inc stock to Outperform with a price target of $14. The latest trade, Performances […]

A Tale from the Dusty Corner: NeuBase Therapeutics Inc (NBSE) Stock

H.C. Wainwright raised the price target for the NeuBase Therapeutics Inc (NASDAQ:NBSE) stock to “a Buy”. The rating was released on February 12, 2021, according to finviz. In their research brief published November 21, 2019, Oppenheimer analysts initiated the NeuBase Therapeutics Inc stock to Outperform with a price target of $14. Historical Earnings Surprises and […]

Why NeuBase Therapeutics Inc (NASDAQ:NBSE) Stock fell -30.18% in Last Six Months?

H.C. Wainwright raised the price target for the NeuBase Therapeutics Inc (NASDAQ:NBSE) stock to “a Buy”. The rating was released on February 12, 2021, according to finviz. In their research brief published November 21, 2019, Oppenheimer analysts initiated the NeuBase Therapeutics Inc stock to Outperform with a price target of $14. Historical Earnings Surprises and […]

NeuBase Therapeutics Inc (NBSE) Stock Has More Upside Than Fundamentals Suggest

H.C. Wainwright raised the price target for the NeuBase Therapeutics Inc (NASDAQ:NBSE) stock to “a Buy”. The rating was released on February 12, 2021, according to finviz. In their research brief published November 21, 2019, Oppenheimer analysts initiated the NeuBase Therapeutics Inc stock to Outperform with a price target of $14. Historical Earnings Surprises and […]